ArticleFrontiers in cardiovascular medicine2025
Influence of Zhigancao decoction on chronic heart failure combined with depression.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the Mechanism of Zhigancao Decoction in the Treatment of Chronic Heart Failure via Modulation of Oxidative Stress.Rapid communications in mass spectrometry : RCM · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic heart failure (CHF) combined with depression represents a significant clinical challenge due to the mutual exacerbation of physical and psychological symptoms. This study investigated the therapeutic effects of Zhigancao decoction, a traditional Chinese medicine, in combination with conventional Western treatments in patients with CHF and depression. A total of 122 patients were enrolled and divided into two groups: a control group receiving standard Western treatment, and an observation group receiving Zhigancao decoction in addition to conventional therapy. Outcomes were assessed by evaluating the clinical efficacy, cardiac function, inflammatory markers, depressive symptoms, and quality of life. The Zhigancao decoction group exhibited significantly higher efficacy rates, improved left ventricular ejection fraction (LVEF), reduced levels of inflammatory markers [N-terminal pro-brain natriuretic peptide (NT-proBNP), matrix metalloproteinase-9 (MMP-9), and high-sensitivity C-reactive protein (hs-CRP)], and lower scores on depression scales, compared to the control group. Furthermore, the quality of life significantly improved in the Zhigancao decoction group. These findings underscore the potential of Zhigancao decoction as an effective adjunct to conventional treatments for managing CHF combined with depression, offering a holistic approach that integrates physical and mental health improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.